How to Help Your Patients Find Yusimry in Stock: A Provider's Guide

When patients call your office because they can't fill their Yusimry prescription, what's your action plan? In 2026, finding Yusimry requires navigating a complex landscape of specialty pharmacy channels, insurance formularies, and alternative access routes. This guide gives you the practical tools and talking points to help your patients get their medication without spending excessive staff time on each case.

Why Your Patients Are Having Trouble Filling Yusimry

The core issue is market access, not manufacturing. Yusimry (adalimumab-aqvh) launched in July 2023 at the lowest list price of any adalimumab biosimilar — $995 per carton, about 85% below Humira — but without private-label deals with the three major PBMs (CVS Caremark, Express Scripts, OptumRx). As a result, pharmacies in these networks have minimal incentive to stock Yusimry, and it holds only a small fraction of adalimumab market share.

Additionally, Yusimry does not have FDA interchangeable designation, so pharmacists cannot substitute it for Humira on their own initiative. Your patients need an explicit Yusimry prescription — and then they need to find a pharmacy that carries it.

Step 1: Verify Formulary Coverage Before You Prescribe

The single most effective thing you can do is check formulary coverage before prescribing. Ask your staff to confirm:

Which PBM manages the patient's pharmacy benefit?

Is Yusimry on the formulary, and at what tier?

Which adalimumab biosimilar is preferred (to use as backup or to write initially)?

Is prior authorization required, and what documentation does the plan need?

If Yusimry isn't on the patient's formulary, consider writing for the formulary-preferred adalimumab biosimilar from the start — or use flexible prescription language ("adalimumab biosimilar — dispense as formulary allows") so the pharmacy can fill what's covered.

Step 2: Identify the Right Pharmacy Channel

Adalimumab biosimilars are specialty medications. Match the patient to the right channel:

In-network specialty pharmacy: Most insurance plans require specialty pharmacy dispensing. Identify which specialty pharmacy is in-network (Accredo for Express Scripts, CVS Specialty for Caremark, Optum Specialty for OptumRx) and send the prescription there directly.

Cost Plus Drugs (costplusdrugs.com): For uninsured, underinsured, or patients with high-deductible plans, Cost Plus Drugs offers Yusimry for $569.27 plus dispensing and shipping — no insurance required.

medfinder (medfinder.com/providers): medfinder calls pharmacies near your patient to check which ones can fill their Yusimry prescription. Your staff can refer patients there instead of spending office time calling pharmacies.

Step 3: Streamline Prior Authorization

Prior authorization (PA) is standard for all biologic medications. To reduce turnaround time:

Submit PA requests electronically through your EHR when possible

Include diagnosis with severity scoring (DAS28, CDAI, PASI, etc.)

Document prior treatment history and any relevant step therapy completion

Note patient tolerance and stability history on this specific product if applicable

PA approval typically takes 2-4 weeks. If you have a patient running low, note "medical urgency" in the PA and ask for an expedited review (generally completed within 72 hours for urgent cases).

Step 4: Connect Patients with Savings Programs

Two key programs can dramatically reduce Yusimry costs for your patients:

Yusimry Solutions Copay Card: For commercially insured patients. Reduces out-of-pocket cost to as little as $0 per prescription (maximum $100 savings per 28-day supply). Call 1-800-987-4679 or visit patient.yusimry.com. Ask your office staff to enroll eligible patients at the point of prescribing.

Cost Plus Drugs: For uninsured, underinsured, or patients on high-deductible plans. $569.27 per 2-pen carton plus dispensing/shipping fees. E-prescribe to costplusdrugs.com.

Step 5: Have a Backup Plan — Know the Formulary-Preferred Alternatives

If Yusimry simply cannot be obtained for a patient, be prepared to switch to the formulary-preferred adalimumab biosimilar. Clinical evidence from the NOR-SWITCH trial and real-world studies confirms that switching between adalimumab products is safe with no increase in adverse events, immunogenicity, or efficacy loss. Major professional societies (ACR, AGA, AAD) support appropriate biosimilar switching for formulary or cost reasons.

Keep a current cheat sheet of your region's most common PBM-preferred adalimumab biosimilars and their specialty pharmacy channels, and review it at least twice yearly as formularies change.

See also our full clinical overview: Yusimry Shortage: What Providers and Prescribers Need to Know in 2026.